HCM
PETX

Hollencrest Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Hollencrest Capital Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-25,000
Closed -$90K – 339
2019
Q1 		$90K Hold
25,000
– – 0.01% 308
2018
Q4 		$153K Hold
25,000
– – 0.02% 264
2018
Q3 		$90K Buy
+25,000
New +$125K 0.01% 308

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Hollencrest Capital Management's PETX Position: Q2 2019 in Review

Hollencrest Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 25,000 shares — an estimated $90K sold.

Hollencrest Capital Management first reported a position in PETX in Q3 2018 and held it in 3 quarters. The position peaked at $153K in Q4 2018. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

  • Hollencrest Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Hollencrest Capital Management sold 25,000 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $90K.
  • Hollencrest Capital Management first reported a position in Aratana Therapeutics, Inc. in Q3 2018 and held it in 3 quarters.
  • Hollencrest Capital Management's Aratana Therapeutics, Inc. position peaked at $153K in Q4 2018.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Hollencrest Capital Management's 13F filing for Q2 2019, filed 18 Jul 2019.